These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24556418)

  • 1. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference.
    Majumder P; Bhunia S; Bhattacharyya J; Chaudhuri A
    J Control Release; 2014 Apr; 180():100-8. PubMed ID: 24556418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomally encapsulated CDC20 siRNA inhibits both solid melanoma tumor growth and spontaneous growth of intravenously injected melanoma cells on mouse lung.
    Mukherjee A; Bhattacharyya J; Sagar MV; Chaudhuri A
    Drug Deliv Transl Res; 2013 Jun; 3(3):224-34. PubMed ID: 25788131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor growth inhibition through targeting liposomally bound curcumin to tumor vasculature.
    Mondal G; Barui S; Saha S; Chaudhuri A
    J Control Release; 2013 Dec; 172(3):832-40. PubMed ID: 24036260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma.
    Bhunia S; Radha V; Chaudhuri A
    Nanoscale; 2017 Jan; 9(3):1201-1212. PubMed ID: 28045167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
    J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature.
    Barui S; Saha S; Mondal G; Haseena S; Chaudhuri A
    Biomaterials; 2014 Feb; 35(5):1643-56. PubMed ID: 24239109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor.
    Mondal G; Barui S; Chaudhuri A
    Biomaterials; 2013 Aug; 34(26):6249-60. PubMed ID: 23702147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes.
    Hemati M; Haghiralsadat F; Jafary F; Moosavizadeh S; Moradi A
    Int J Nanomedicine; 2019; 14():6575-6585. PubMed ID: 31616144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
    Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
    Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
    J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of CDC20 via small interfering RNA causes enhancement of the cytotoxicity of chemoradiation.
    Taniguchi K; Momiyama N; Ueda M; Matsuyama R; Mori R; Fujii Y; Ichikawa Y; Endo I; Togo S; Shimada H
    Anticancer Res; 2008; 28(3A):1559-63. PubMed ID: 18630511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Antitumor Efficacy of RNAi-Mediated Inhibition of CDC20 and Heparanase in an Orthotopic Liver Tumor Model.
    Liu M; Zhang Y; Liao Y; Chen Y; Pan Y; Tian H; Zhan Y; Liu D
    Cancer Biother Radiopharm; 2015 Aug; 30(6):233-9. PubMed ID: 26132704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth.
    Samanta S; Sistla R; Chaudhuri A
    Biomaterials; 2010 Mar; 31(7):1787-97. PubMed ID: 19889452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
    Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.
    Yang ZZ; Li JQ; Wang ZZ; Dong DW; Qi XR
    Biomaterials; 2014 Jun; 35(19):5226-39. PubMed ID: 24695093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system.
    Kim SW; Kim NY; Choi YB; Park SH; Yang JM; Shin S
    J Control Release; 2010 May; 143(3):335-43. PubMed ID: 20079391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.
    Aleku M; Schulz P; Keil O; Santel A; Schaeper U; Dieckhoff B; Janke O; Endruschat J; Durieux B; Röder N; Löffler K; Lange C; Fechtner M; Möpert K; Fisch G; Dames S; Arnold W; Jochims K; Giese K; Wiedenmann B; Scholz A; Kaufmann J
    Cancer Res; 2008 Dec; 68(23):9788-98. PubMed ID: 19047158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.